Ocular Therapeutix, INC Form 4 insider transactions

Director Adrienne L. Graves received stock and option grants from Ocular Therapeutix, Inc. on July 24, 2024.

Nadia Waheed, Chief Medical Officer of Ocular Therapeutix, reports the acquisition of restricted stock units and stock options.

Sanjay Nayak, Chief Strategy Officer of Ocular Therapeutix, sold 2,274 shares of common stock to cover tax obligations related to vesting restricted stock units.

Pravin Dugel, Executive Chairman, President, and CEO of Ocular Therapeutix, sold shares to cover tax obligations related to vesting restricted stock units.

Summer Road LLC, a family office, purchased 930,851 shares of Ocular Therapeutix (OCUL) at $7.52 per share through a private placement.